www.diseases-diagnosis.com Homepage Diseases Symptoms Diseases Diagnosis Diseases Treatment Diseases Living Care Diseases Prevention Diseases Research
www
Search
Thursday, September 14th, 2017
Table of Contents

1 Introduction
5 PMID
 [F] Diseases Research  / PubMed Research Articles  /
The projected burden of osteoarthritis and rheumatoid arthritis in Australia: A population-level analysis.

PubMed

 

Resource

Arthritis care & research 2017 Sep 12; ()

Authors

Ackerman IN1; Pratt C2; Gorelik A3; Liew D4;

Author Information
  • 1Monash University, Melbourne, Australia; and The University of Melbourne, Melbourne, Australia.
  • 2Formerly Department of Medicine (Royal Melbourne Hospital), The University of Melbourne, Australia.
  • 3Melbourne EpiCentre, Royal Melbourne Hospital, The University of Melbourne, Australia.
  • 4Monash University, Melbourne, Australia; and The University of Melbourne, Melbourne, Australia.

Abstract

OBJECTIVE: To forecast the prevalence and direct healthcare costs of osteoarthritis (OA) and rheumatoid arthritis (RA) in Australia to the year 2030.

METHODS: An epidemiological model of the Australian population was developed. Data on the national prevalence of OA and RA were obtained from the Australian Bureau of Statistics (ABS) 2014-2015 National Health Survey. Future prevalence was estimated using ABS population projections for 2020, 2025 and 2030. Available government data on direct healthcare expenditure for OA and RA were modelled to forecast costs (in AUD) for the years 2020, 2025 and 2030, from the perspective of the Australian public healthcare system.

RESULTS: The number of people with OA is expected to increase nationally from almost 2.2 million in 2015 to almost 3.1 million Australians in 2030. The number of people with RA is projected to increase from 422,309 in 2015 to 579,915 in 2030. Healthcare costs for OA were estimated to be over $2.1 billion in 2015; by the year 2030, these are forecast to exceed $2.9 billion ($970 for every person with the condition). Healthcare costs for RA were estimated to be over $550 million in 2015, including $273 million spent on biological disease-modifying anti-rheumatic drugs. Healthcare costs for RA are projected to rise to over $755 million by the year 2030.

CONCLUSIONS: OA and RA are costly conditions that will impose an increasing healthcare burden at the population level. These projections provide tangible data that can be utilised to map future health service provision to expected need. This article is protected by copyright. All rights reserved.

This article is protected by copyright. All rights reserved.

PMID

28898565

Others

Publication Type: Journal Article


This article is licensed under the the National Library of Medicine License. It uses material from the PubMed National Library of Medicine Data.


Last Modified:   2016-03-27


Search
All informatin on the site is © www.diseases-diagnosis.com 2002-2016. Last revised: March 27, 2016
Are you interested in our site or/and want to use our information? please read how to contact us and our copyrights.
To let us provide you with high quality information, you can help us by making a more or less donation: